N/A N=52 Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
Post Traumatic Stress Disorder · Opioid-use Disorder
Primary: Change in Posttraumatic Stress Disorder (PTSD) Symptom Severity — -11.4; -12.8; -18.3 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=143 SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Type 2 Diabetes (T2D) Who Had Prescription Changes in Concordance With SSCVD Results — 45; 13; 8; 35 Participants
Phase 2 N=7 Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
Breast Cancer · Chronic Pain Due to Malignancy (Finding)
Primary: Overall Pain Relief. — 1.9; 0.5 score on a scale
N/A N=960 PrEPARE: PrEP in Pregnancy, Accelerating Reach and Efficiency
Pre-Exposure Prophylaxis · HIV Infections · Pregnancy Related
Primary: PrEP Penetration — 30; 17; 46; 8 Participants
Phase 2 N=252 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Advanced Unresectable or Metastatic Solid Malignancy
Primary: Confirmed Objective Response Rate (ORR) Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Response…
N/A N=21 Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia
Cerebellar Ataxia · Spinocerebellar Ataxias · Cerebellar Degeneration
Primary: Change in Overt Tapping Accuracy as Assessed by Finger Tapping to a Flashing Cue at 1Hz Speed — .00141488 taps per second
Phase 2 N=28 Developing Oral LT3 Therapy for Heart Failure - HFpEF
Heart Failure With Preserved Ejection Fraction · Low Triiodothyronine Syndrome
Primary: Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats — 10; 12 Number of participants with events
N/A N=100 Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Sleep Disturbance — 62.1; 62.4; 57.7; 58.3 T-score
Phase 1 N=9 A GBT021601 ADME Microtracer Study in Healthy Volunteers
Sickle Cell Disease
Primary: GBT021601 Concentration in Whole Blood and Plasma at Predose — NA; NA Microgram/ milliliter (mcg/mL)
Phase 2 N=309 A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
Meningococcal Vaccine
Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer >=Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…
Phase 2 N=30 Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure
Primary: Change in Exercise Pulmonary Capillary Wedge Pressure (PCWP) — -1; -4 mmHg — p=0.040
Phase 2 N=126 N-Acetylcysteine for Adolescent Alcohol Use Disorder
Alcohol Use Disorder
Primary: Alcohol Use During the Final 4 Weeks of Treatment (Weeks 5 - 8) — 37.9; 42.6 Standard drinks
Phase 2 N=45 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
X-Linked Retinitis Pigmentosa
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…
N/A N=38 An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio